182 related articles for article (PubMed ID: 31749072)
1. Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.
Vornov JJ; Peters D; Nedelcovych M; Hollinger K; Rais R; Slusher BS
Neurochem Res; 2020 Jun; 45(6):1256-1267. PubMed ID: 31749072
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
Evans JC; Malhotra M; Cryan JF; O'Driscoll CM
Br J Pharmacol; 2016 Nov; 173(21):3041-3079. PubMed ID: 27526115
[TBL] [Abstract][Full Text] [Related]
3. Parallel Metabolomics and Lipidomics of a PSMA/GCPII Deficient Mouse Model Reveal Alteration of NAAG Levels and Brain Lipid Composition.
Sedlák F; Kvasnička A; Marešová B; Brumarová R; Dobešová D; Dostálová K; Šrámková K; Pehr M; Šácha P; Friedecký D; Konvalinka J
ACS Chem Neurosci; 2024 Apr; 15(7):1342-1355. PubMed ID: 38377674
[TBL] [Abstract][Full Text] [Related]
4. Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease.
Date AA; Rais R; Babu T; Ortiz J; Kanvinde P; Thomas AG; Zimmermann SC; Gadiano AJ; Halpert G; Slusher BS; Ensign LM
J Control Release; 2017 Oct; 263():132-138. PubMed ID: 28159515
[TBL] [Abstract][Full Text] [Related]
5. A method to determine the mode of binding for GCPII inhibitors using bio-layer interferometry.
Choy CJ; Berkman CE
J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1690-3. PubMed ID: 26873576
[TBL] [Abstract][Full Text] [Related]
6. Combination of
Temml V; Kollár J; Schönleitner T; Höll A; Schuster D; Kutil Z
J Chem Inf Model; 2023 Feb; 63(4):1249-1259. PubMed ID: 36799916
[TBL] [Abstract][Full Text] [Related]
7. Gender and disease-inclusive nomenclature consolidation of theragnostic target, prostate-specific membrane antigen (PSMA) to folate hydrolase-1 (FOLH1).
Ramirez-Fort MK; Gilman CK; Alexander JS; Meier-Schiesser B; Gower A; Olyaie M; Vaidya N; Vahidi K; Li Y; Lange CS; Fort M; Deurdulian C
Front Med (Lausanne); 2023; 10():1304718. PubMed ID: 38444631
[No Abstract] [Full Text] [Related]
8. Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer.
Staniszewska M; Iking J; Lückerath K; Hadaschik B; Herrmann K; Ferdinandus J; Fendler WP
Nucl Med Biol; 2021; 96-97():101-111. PubMed ID: 33866131
[TBL] [Abstract][Full Text] [Related]
9. PSMA-Targeted PET Radiotracer [
Ismail MS; Peters DE; Rowe SP; Salavati A; Sharma S; Anders RA; Pomper M; Slusher BS; Selaru FM
Clin Exp Gastroenterol; 2023; 16():237-247. PubMed ID: 38090679
[TBL] [Abstract][Full Text] [Related]
10. A gut-restricted glutamate carboxypeptidase II inhibitor reduces monocytic inflammation and improves preclinical colitis.
Peters DE; Norris LD; Tenora L; Šnajdr I; Ponti AK; Zhu X; Sakamoto S; Veeravalli V; Pradhan M; Alt J; Thomas AG; Majer P; Rais R; McDonald C; Slusher BS
Sci Transl Med; 2023 Aug; 15(708):eabn7491. PubMed ID: 37556558
[TBL] [Abstract][Full Text] [Related]
11. D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase II.
Gori SS; Thomas AG; Pal A; Wiseman R; Ferraris DV; Gao RD; Wu Y; Alt J; Tsukamoto T; Slusher BS; Rais R
Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297453
[TBL] [Abstract][Full Text] [Related]
12. Advances in PSMA theranostics.
Jeitner TM; Babich JW; Kelly JM
Transl Oncol; 2022 Aug; 22():101450. PubMed ID: 35597190
[TBL] [Abstract][Full Text] [Related]
13. Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors.
Stopa BM; Crowley J; Juhász C; Rogers CM; Witcher MR; Kiser JW
Mol Imaging; 2022; 2022():5358545. PubMed ID: 35517711
[TBL] [Abstract][Full Text] [Related]
14.
Morland C; Nordengen K
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163193
[No Abstract] [Full Text] [Related]
15. Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells.
Bakht MK; Hayward JJ; Shahbazi-Raz F; Skubal M; Tamura R; Stringer KF; Meister D; Venkadakrishnan VB; Xue H; Pillon A; Stover M; Tronchin A; Fifield BA; Mader L; Ku SY; Cheon GJ; Kang KW; Wang Y; Dong X; Beltran H; Grimm J; Porter LA; Trant JF
Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35064078
[TBL] [Abstract][Full Text] [Related]
16. Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases.
Honig G; Larkin PB; Heller C; Hurtado-Lorenzo A
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S1-S16. PubMed ID: 34791292
[TBL] [Abstract][Full Text] [Related]
17. Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue.
Yuan W; Liu B; Sanda M; Wei R; Benicky J; Novakova Z; Barinka C; Goldman R
Prostate; 2022 Jan; 82(1):132-144. PubMed ID: 34662441
[TBL] [Abstract][Full Text] [Related]
18. PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives.
El Fakiri M; Geis NM; Ayada N; Eder M; Eder AC
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439121
[TBL] [Abstract][Full Text] [Related]
19. PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?
Brenner W; Strobel J; Prasad V
J Nucl Med; 2021 Sep; 62(9):1242-1243. PubMed ID: 34272320
[No Abstract] [Full Text] [Related]
20. A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the Spotlight.
Cuthbertson CR; Arabzada Z; Bankhead A; Kyani A; Neamati N
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):624-646. PubMed ID: 33860190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
